Related Experiment Videos
Effects of phorbol ester on cell growth inhibition by transforming growth factor beta 1 in human hepatoma cell lines
1Second Department of Internal Medicine, Osaka University Medical School, Japan.
Abstract:
The effects of phorbol ester on cell growth inhibition by transforming growth factor beta 1 (TGF-beta 1) in human hepatoma cell lines, Mahlavu and PLC/PRF/5, were investigated. TGF-beta 1 (2.5 to 10 pM) alone could not inhibit the growth of Mahlavu cells, whereas in the presence of 12-O-tetradecanoyl phorbol 13-acetate (TPA) at 1 ng/ml, TGF-beta 1 could suppress their growth in a dose-dependent manner. The growth of PLC/PRF/5 cells could be inhibited by addition of TGF-beta 1 (2.5 to 10 pM) alone in a dose-dependent manner, and this action was not affected by TPA (1 ng/ml). The TGF-beta 1 inhibition induced by TPA in Mahlavu cells could not be cancelled by addition of protein kinase C inhibitor, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H7) (10 microM) or staurosporin (1 nM). Thus, TPA could induce TGF-beta 1 inhibition of cell growth in Mahlavu cells which did not respond to TGF-beta 1 alone, and activation of protein kinase C does not seem to be behind this TPA action.
Insights
Phorbol ester (TPA) enables transforming growth factor beta 1 (TGF-beta 1) to inhibit Mahlavu hepatoma cell growth, a feat not achieved by TGF-beta 1 alone. This TPA-induced effect on cell growth inhibition does not involve protein kinase C activation.
Area of Science:
- Hepatocellular carcinoma research
- Cell signaling pathways
- Cancer biology
Background:
- Transforming growth factor beta 1 (TGF-beta 1) is a key regulator of cell growth and differentiation.
- Human hepatoma cell lines Mahlavu and PLC/PRF/5 are used to study liver cancer mechanisms.
- Phorbol esters, like 12-O-tetradecanoyl phorbol 13-acetate (TPA), are known modulators of cellular processes.
Purpose of the Study:
- To investigate the role of phorbol ester (TPA) in modulating TGF-beta 1-induced cell growth inhibition in human hepatoma cells.
- To determine if TPA can sensitize TGF-beta 1-resistant hepatoma cells to growth inhibition.
- To elucidate the signaling pathway involved in TPA's effect on TGF-beta 1-mediated growth suppression.
Main Methods:
- Treatment of Mahlavu and PLC/PRF/5 cells with varying concentrations of TGF-beta 1.
- Co-treatment experiments involving TGF-beta 1 and TPA.
- Assessment of cell growth inhibition.
- Inhibition studies using protein kinase C inhibitors (H7 and staurosporine).
Main Results:
- TGF-beta 1 alone did not inhibit Mahlavu cell growth but did inhibit PLC/PRF/5 cells in a dose-dependent manner.
- TPA (1 ng/ml) enabled TGF-beta 1 to inhibit Mahlavu cell growth dose-dependently.
- TPA did not affect TGF-beta 1's growth inhibitory action on PLC/PRF/5 cells.
- Protein kinase C inhibitors (H7, staurosporine) did not reverse the TPA-induced TGF-beta 1 effect in Mahlavu cells.
Conclusions:
- TPA can induce sensitivity to TGF-beta 1-mediated growth inhibition in Mahlavu hepatoma cells that are otherwise resistant.
- The mechanism by which TPA enhances TGF-beta 1's growth inhibitory effect in Mahlavu cells does not appear to involve protein kinase C activation.
- These findings suggest novel therapeutic strategies targeting cell growth pathways in specific hepatoma subtypes.